Uniqure NV
NASDAQ:QURE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.78
10.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Uniqure NV
Uniqure NV
Cash Interest Paid
Uniqure NV
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uniqure NV
NASDAQ:QURE
|
Cash Interest Paid
$20.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
48%
|
CAGR 10-Years
25%
|
|
|
Pharming Group NV
AEX:PHARM
|
Cash Interest Paid
$2.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cash Interest Paid
€1.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
87%
|
CAGR 10-Years
N/A
|
|
|
argenx SE
XBRU:ARGX
|
Cash Interest Paid
$290k
|
CAGR 3-Years
-24%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's Cash Interest Paid?
Cash Interest Paid
20.8m
USD
Based on the financial report for Sep 30, 2024, Uniqure NV's Cash Interest Paid amounts to 20.8m USD.
What is Uniqure NV's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 10Y
25%
Over the last year, the Cash Interest Paid growth was 32%. The average annual Cash Interest Paid growth rates for Uniqure NV have been 58% over the past three years , 48% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
